As part of export promotion initiative, GEROPHARM Group of Companies starts to supply original Russian medicine Cortexin® to Turkey.
Turkey is one of strategic and prospective new markets for the
company: the country is in the TOP 10 biggest European pharmaceutical
markets, the country population is of about 80 million people. Exports
to Turkey are the first step of GEROPHARM towards export expansion in
the Middle East.
GEROPHARM will supply Cortexin® according to the private
treatment scheme, which means provision of medical care for certain
patients required on therapeutic grounds. In June 2015, Turkish FDA
(TürkiyeİlaçveTıbbiCihazKurumu) included this product in the list of
medications approved for import to the country under doctors’ requests
for certain patients by the Ministry of Health of Turkey.
“We are convinced that Russian original drug products have a great export potential,” says Petr Rodionov, Head of GEROPHARM Group. “Our drug products have earned the confidence of Russian doctors and patients as the result of many years of successful application. Current manufacturing standards of the company comply with the international ones, the GEROPHARM-Bio plant has an international GMP (PIC/SGMP) certificate. We conduct all new researches, whether of original products or generics and biosimilars, in compliance with the international standards. This also applies to analogue insulins which we plan to supply not only to the Russian market, but to international markets as well”.